Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
This article was originally published in Pharmaceutical Approvals Monthly
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.
You may also be interested in...
Onyx dropped its lawsuit against partner Bayer in exchange for an agreement that lets it share the financial rewards of the compound at the heart of the controvers, regorafenib, now in Phase III for oncology indications.
Onyx Pharmaceuticals Inc.’s growing pipeline, including one high-profile compound finishing successful Phase II clinical trials, appears to be finally moving the company beyond its considerable reliance on its flagship cancer drug Nexavar (sorafenib).
Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.